Paul Rodriguez, MD

Articles by Paul Rodriguez, MD

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

ByMehmet Sitki Copur, MD, FACP,Caleb W. Schroeder, MD,Quan Ly, MD,Whitney Wedel, MD,Jacqueline R. Kelly, MD, MSc,Paul Rodriguez, MD,Soe Min Tun, MD, MBA, MSc,Nicholas Lintel, MD,Adam J. Horn, MD,Bronson Riley, CGC

February 15th 2022

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord Compression

ByMehmet Sitki Copur, MD,Scott Bell, MD, PhD, MPH,Paul Rodriguez, MD,Whitney Wedel, MD,Nicholas Lintel, MD,Thomas Zusag, MD,John L. Allen, MD

March 18th 2021

Mehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.

Recurrent EGFR-Mutated Non–Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options

ByMehmet Sitki Copur, MD,Rudy P. Lackner, MD,Adam J. Horn, MD,Thomas Zusag, MD,Shellie Faris, MD,Paul Rodriguez, MD

September 21st 2020

ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.